- Home
- BTE vs TNGX Comparison
BTE vs TNGX Comparison
Compare BTE & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTE
- TNGX
- Stock Information
- Founded
- BTE 1993
- TNGX 2014
- Country
- BTE Canada
- TNGX United States
- Employees
- BTE N/A
- TNGX N/A
- Industry
- BTE Meat/Poultry/Fish
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- BTE Consumer Staples
- TNGX Health Care
- Exchange
- BTE Nasdaq
- TNGX Nasdaq
- Market Cap
- BTE 1.4B
- TNGX 351.2M
- IPO Year
- BTE N/A
- TNGX N/A
- Fundamental
- Price
- BTE $1.84
- TNGX $5.44
- Analyst Decision
- BTE Hold
- TNGX Strong Buy
- Analyst Count
- BTE 1
- TNGX 6
- Target Price
- BTE $5.50
- TNGX $12.20
- AVG Volume (30 Days)
- BTE 65.1M
- TNGX 3.9M
- Earning Date
- BTE 07-24-2025
- TNGX 08-06-2025
- Dividend Yield
- BTE 3.52%
- TNGX N/A
- EPS Growth
- BTE N/A
- TNGX N/A
- EPS
- BTE 0.28
- TNGX N/A
- Revenue
- BTE $2,327,227,884.00
- TNGX $40,990,000.00
- Revenue This Year
- BTE $3.43
- TNGX N/A
- Revenue Next Year
- BTE N/A
- TNGX N/A
- P/E Ratio
- BTE $6.55
- TNGX N/A
- Revenue Growth
- BTE 10.55
- TNGX 10.09
- 52 Week Low
- BTE $1.36
- TNGX $1.03
- 52 Week High
- BTE $3.84
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- BTE 49.05
- TNGX 74.98
- Support Level
- BTE $2.00
- TNGX $4.60
- Resistance Level
- BTE $2.15
- TNGX $5.63
- Average True Range (ATR)
- BTE 0.10
- TNGX 0.56
- MACD
- BTE -0.03
- TNGX -0.05
- Stochastic Oscillator
- BTE 17.44
- TNGX 85.47
About BTE Baytex Energy Corp
Baytex Energy Corp is an oil and gas company. Geographically, the group operates in Canada and the United States. The company derives a majority of revenue from Canada. Its Canada segment includes the exploration, development, and production of crude oil and natural gas in Western Canada.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.